NCT00044863View on ClinicalTrials.gov

Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

August 31, 2002

Primary Completion Date

December 31, 2005

Study Completion Date

December 31, 2005

Conditions
Colorectal NeoplasmsMetastases, Neoplasm
Interventions
BIOLOGICAL

Erbitux (Cetuximab)

400 mg/m2 initial dose, 250 mg/m2 weekly

Trial Locations (1)

63301

ImClone Investigational Site, Saint Charles

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT00044863 - Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma | Biotech Hunter | Biotech Hunter